E-COMMODITIES (01733) announced its interim results, with a profit attributable to shareholders of HK$250 million, an increase of 83.76% year-on-year.
Easy Holding (01733) announced its interim results for the six months ended June 30, 2026, with revenue of HKD 13.987 billion, an increase of 10.38% year-on-year; profit attributable to equity shareholders of HKD 250 million, a year-on-year increase of 83.76%; basic earnings per share of HKD 0.095. A mid-term dividend of HKD 0.023 per share is proposed.
E-COMMODITIES (01733) announced its interim results for the six months ending June 30, 2026, reporting revenue of HKD 13.987 billion, a year-on-year increase of 10.38%; profit attributable to equity shareholders of HKD 250 million, a year-on-year increase of 83.76%; and basic earnings per share of HKD 0.095. The company intends to declare an interim dividend of HKD 0.023 per share.
The announcement stated that in the first half of 2026, the rigid contraction in the domestic coking coal supply led to an upward shift in the price center, gradually restoring the price inversion pattern for domestic and international coking coal. In response to this market environment, the company flexibly mobilized domestic and international resources: on one hand, the company adhered to a global procurement and sales strategy, while on the other, it continued to expand its domestic coal product matrix, effectively diversifying to meet differentiated downstream demand, further broadening domestic sales channels. In the first half of 2026, sales revenue from China (including Hong Kong, Macau, and Taiwan) was HKD 10.907 billion, with the revenue contribution rising from 67.22% during the same period in 2025 to 77.97%. During the period, the company maintained a stable presence in non-China markets, covering multiple countries and regions including Indonesia, Mongolia, South Korea, India, Malaysia, Vietnam, and Canada, achieving sales revenue of HKD 3.080 billion.
Related Articles

MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.

AKESO (09926): The AK112309/HARMONi-GI1 Phase III clinical trial achieved statistically significant positive results in overall survival (OS) when comparing the efficacy of Abraxane combined with gemcitabine to that of Atezolizumab combined with chemotherapy, indicating substantial clinical benefits.
MANULIFE-S (00945) will distribute a second-quarter dividend of CAD 0.485 per share on September 21.

BRETON (01333) expects to incur a loss of approximately 80 million to 90 million yuan in the medium term, narrowing by about 45.93% to 51.67% compared to the same period last year.

AKESO (09926): The AK112309/HARMONi-GI1 Phase III clinical trial achieved statistically significant positive results in overall survival (OS) when comparing the efficacy of Abraxane combined with gemcitabine to that of Atezolizumab combined with chemotherapy, indicating substantial clinical benefits.

RECOMMEND





